NASDAQ:KLTO Klotho Neurosciences (KLTO) Stock Price, News & Analysis $1.23 -0.04 (-3.15%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Klotho Neurosciences Stock (NASDAQ:KLTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Klotho Neurosciences alerts:Sign Up Key Stats Today's Range$1.22▼$1.2850-Day Range$0.17▼$2.0152-Week Range$0.11▼$3.91Volume1.02 million shsAverage Volume13.57 million shsMarket Capitalization$56.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. Read More Receive KLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Klotho Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLTO Stock News HeadlinesUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology | KLTO ...1 hour ago | gurufocus.comUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology2 hours ago | prnewswire.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 25 at 2:00 AM | Timothy Sykes (Ad)Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyJuly 24 at 1:30 PM | prnewswire.comKlotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy AssetsJuly 22 at 10:21 AM | prnewswire.comKlotho Neurosciences regains full compliance with Nasdaq listing standardsJuly 16, 2025 | msn.comKlotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity RulesJuly 16, 2025 | prnewswire.comKlotho Neurosciences stock soars after FDA grants orphan drug status ...July 11, 2025 | uk.investing.comSee More Headlines KLTO Stock Analysis - Frequently Asked Questions How have KLTO shares performed this year? Klotho Neurosciences' stock was trading at $0.4850 at the beginning of 2025. Since then, KLTO shares have increased by 153.6% and is now trading at $1.23. How were Klotho Neurosciences' earnings last quarter? Klotho Neurosciences, Inc. (NASDAQ:KLTO) posted its earnings results on Thursday, May, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. How do I buy shares of Klotho Neurosciences? Shares of KLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2025Today7/25/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KLTO Previous SymbolNASDAQ:KLTO CIK1907223 Webwww.klothoneuro.com Phone(833) 931-6330FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,779.01% Return on Assets-275.01% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book30.75Miscellaneous Outstanding Shares46,053,000Free Float33,757,000Market Cap$56.65 million OptionableN/A Beta11.08 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KLTO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.